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Objective: The objective of this selective EBM review is to determine whether or not MDMA-
assisted psychotherapy (MAP) results in symptom improvement in adults with Posttraumatic 
Stress Disorder (PTSD). 
Study Design: Systematic review of three randomized control trials (RCTs) published between 
2017 and 2018. 
Data Sources: All three RCTs were written in English and published in peer-reviewed journals 
found via PubMed. Each analyzed the effect of MAP on PTSD symptom severity. 
Outcomes Measured: The primary outcome in all three studies was PTSD symptom changes. 
The Clinician-Administered PTSD Scale (CAPS-IV) and NEO PI-R Personality Inventory 
(NEO) were used to assess symptoms before and after intervention. 
Results: All three studies showed improvement in PTSD symptoms after MAP, but only one of 
these studies had results reaching statistical significance without eliminating outlier data. 
Specifically, Mithoefer et al. found a CAPS-IV mean difference of -11.4 for the 30 mg group and 
-44.3 for the 125 mg group, with a statistically significant p-value of 0.004 (Lancet Psychiatry. 
2018;5(6):486-497. doi: S2215-0366(18)30135-4 [pii]). 
Conclusions: There is not enough statistically significant data to conclude that MAP improves 
PTSD symptoms. Future studies with larger, more diverse populations must be conducted to 
strengthen the statistical significance and generalizability of Mithoefer et al.’s findings. 
Moreover, drug accessibility and treatment monitoring must be considered as limiting factors to 
implementing MAP.   
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INTRODUCTION 
Posttraumatic stress disorder (PTSD) is a psychiatric condition characterized by having 
flashbacks, overwhelmingly negative emotions, and avoidant behavior that begins or persists for 
more than one month following a traumatic event. Symptoms can be debilitating and linger for 
years and current treatment options demonstrate only minimal effectiveness. It is also a relatively 
common disorder when considering that 33% of the population endures a traumatic experience 
that places them at risk for PTSD and 25% of those individuals will go on to develop PTSD.1 In 
2005, the Veterans Benefits Administration reported that PTSD was the most expensive 
diagnosis for the Veterans Administration.2 Among veterans alone, the annual treatment cost for 
PTSD is estimated to be $600 million.3 The commonality and cost associated with PTSD make it 
necessary to identify effective treatment options.  
PTSD affects a large, heterogeneous portion of the population and can be a chronic, 
disruptive, and debilitating condition. Research is still needed to determine which combination of 
treatment modalities results in the most effective management of symptoms. Cognitive behavior 
therapy is the psychotherapeutic treatment of choice for PTSD, while selective serotonin 
reuptake inhibitors are considered the first line pharmacologic treatment. Paroxetine and 
sertraline are the only two drugs approved by the FDA for PTSD. Propranolol, clonidine, and 
trazadone are often prescribed for off-label use, but getting insurance approval for this is often 
difficult. A recent study found that among individuals recently diagnosed with primary PTSD, 
over half received no therapy sessions, 10% received > 12 therapy sessions in the first 6 months 
following diagnosis, and 47% received psychiatric prescriptions.4 Additionally, 28% of patients 
received no treatment, 19% only received pharmacotherapy, 27.6% only receive
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therapy, and 25.3% received therapy and pharmacotherapy.4 These findings suggest a mixed 
picture of treatment approaches and healthcare utilization.  
PTSD is a common diagnosis with treatment options that are limited in number and 
effectiveness.  Only two drugs with similar mechanisms of action are FDA-approved for PTSD 
treatment. For patients with refractory symptoms, additional medications are often prescribed for 
off-label use, but their efficacy has not been extensively studied in the context of PTSD. 
Psychotherapy is considered to be more effective than medications in treating PTSD, but dropout 
rates are high, in part because of the disease itself and patients’ avoidant behavior.   
3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic Schedule I drug that is 
structurally similar to amphetamines. It acts by influencing the amount of monoamine 
neurotransmitters available in synapses, predominantly serotonin.5 Psychological effects that 
have been associated with MDMA include increased empathy, improved mood, and a heightened 
desire for connection to others.5 Psychotherapy coupled with MDMA administration may allow 
patients to better process their trauma, connect with their therapist, and more effectively manage 
their PTSD. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not MDMA-
assisted psychotherapy (MAP) results in symptom improvement in adults with PTSD. 
METHODS 
 The key words “MDMA” and “PTSD” were searched in PubMed. Only articles that were 
primary resources, written in English and published in peer-reviewed journals after August 2017 
were considered. Systematic reviews and patient populations that included individuals < 18 years 
old were excluded.  
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Three double-blind randomized control trials that met the above criteria were selected for 
review. Each trial contained a population of males and females who were > 18 years old and had 
been diagnosed with PTSD based on DSM-IV or DSM-IV-TR criteria. The intervention being 
studied in each trial was MAP. All three trials measured PTSD symptom severity before and 
after intervention using statistical values such as numbers needed to treat (NNT), absolute benefit 
increase (ABI), relative benefit increase (RBI), p-values, and/or mean changes.  
Two trials compared the outcomes of psychotherapy with a low inactive dose of MDMA 
to the same psychotherapy assisted by one of two different higher active doses of MDMA.6,7 
Wagner et al. compared the outcomes of psychotherapy with 125 mg of MDMA to the outcomes 
of the same psychotherapy assisted only by a placebo.8 Table 1 summarizes the demographics 
and characteristics of the studies included in this review.  
Table 1  Demographics & Characteristics of included studies 
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OUTCOMES MEASURED 
 The primary outcome in each study was PTSD symptom improvement. Two studies used 
the Clinician-Administered PTSD Scale (CAPS-IV) to assess symptom improvement, which is a 
gold standard, semi-structured interview that quantifies PTSD symptoms through diagnostic and 
symptom severity scores. Blinded independent raters conducted CAPS-IV interviews. Higher 
scores are associated with more severe PTSD. Wagner et al. measured symptom improvement by 
evaluating changes in key personality traits associated with PTSD. They did this by comparing 
openness and neuroticism variables from the NEO PI-R Personality Inventory (NEO) before and 
after psychotherapy sessions assisted by placebo or MDMA. The NEO PI-R is a well-validated, 
240-item self-report tool that has been used for decades to define personality. The higher the 
score for a trait, the more the individual embodies that trait.
RESULTS 
The study completed by Ot’alora et al.6 in 2018 was a double blind control study that 
enrolled and consented 28 patients who met the criteria outlined in Table 1. Baseline CAPS-IV 
scores were collected. Three 90-minute sessions of psychotherapy were conducted prior to 
MDMA administration to build rapport and foster a safe environment. Psychiatric medications 
were tapered and discontinued before patients were randomized to one of three dose groups (40 
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mg, 100 mg, or 125 mg). Two 8-hour MDMA blinded sessions were completed a month apart. 
Integrative sessions were completed the day after MDMA sessions to assess subjects’ wellness 
and discuss the experiences and insights gained during the experimental session. Patients also 
received phone calls daily for one week following each experimental session. CAPS-IV scores 
were reassessed one month after the second blinded experimental session, which served as the 
study’s primary endpoint. At this time, the blind was broken and a crossover portion of the study 
was completed. This review focuses on the primary endpoint findings for the 40 mg and 125 mg 
groups.  
No serious adverse events (SAEs) occurred in this study during the blinded portion.6 
Three SAEs were reported during later portions of the study, but none of them were considered 
related to MDMA.6 There were dose related changes in heart rate and systolic blood pressure, 
which rose as the dose rose, but no medical interventions were required.6 
There were originally six participants in the 40 mg low dose group, nine participants in 
the 100 mg high dose group, and 13 participants in the 125 mg high dose group. One participant 
from the 40 mg group discontinued treatment after just one blinded MDMA session because 
efficacy was attained.6 This individual completed primary outcome assessments and was 
included in the intention-to-treat (ITT) analysis but not the per protocol (PP) analysis. One 
participant from the 125 mg group withdrew from the study for undisclosed reasons before 
completing primary outcome assessments.6 This individual’s data could not be assessed in ITT or 
PP analyses. Three additional participants in the 125 mg group were included in ITT analysis but 
excluded from PP analysis because they withheld psychiatric diagnoses during the screening 
period that would have excluded them from participating.6 
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CAPS-IV total scores at baseline were compared to CAPS-IV scores one month after the 
second experimental session by using an analysis of variance (ANOVA) with α = 0.05. 
Descriptive statistics were used to convey the percentage of subjects that no longer met CAPS-
IV PTSD diagnostic criteria at the primary endpoint. Pre- and post-treatment values are 
summarized in Tables 2a, 2b, and 3. 
In the ITT set, the 40 mg group had a baseline CAPS-IV total score of 84.8 and a post-
experimental session total score of 73.3, which represents an 11.5 decrease.6 The 125 mg group 
had a baseline CAPS-IV total score of 93.5 and a post-experimental session total score of 64.3, 
which represents a 26.3 decrease and a p = 0.27 compared to the 40mg group.6 In the PP set, the 
40 mg group had a baseline CAPS-IV total score of 84.6 and a post-experimental session total 
score of 80.6, which represents a 4.0 decrease.6 The 125 mg group had a baseline CAPS-IV total 
score of 91.6 and a post-experimental session total score of 54.6, which represents a 37.0 
decrease and a p = 0.01 compared to the 40 mg group.6 At baseline, all participants in the 40 mg 
and 125 mg groups met CAPS-IV criteria for the diagnosis of PTSD. After two blinded MDMA 
sessions, 2 of the 6 subjects (33.3%) in the 40 mg group and 5 of the 12 subjects (41.7%) in the 
125 mg group no longer met CAPS-IV criteria for PTSD.6 
The control event rate (CER) was 0.667, the experimental event rate (EER) was 0.583, 
the absolute benefit increase (ABI) was 0.084, the relative benefit increase (RBI) was 0.13, and 
the numbers needed to treat (NNT) was 12. These values are summarized in Table 4. 
Table 2a CAPS-IV total scores, mean (SD), ITT 
Intention to Treat Set 
 Baseline Post 2 blinded 
sessions 
Change P Valuea 
40 mg MDMA 84.8 (8.0) 73.3 (24.5) -11.5 (21.2) -- 
125 mg 
MDMA 
93.5 (20.0) 64.3 (33.6) -26.3 (29.5) 0.27 
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Table 2b CAPS-IV total scores, mean (SD), PP 
Per Protocol Set 
 Baseline Post 2 blinded 
sessions 
Change P Value a 
40 mg MDMA 84.6 (9.0) 80.6 (18.8) -4.0 (11.9) -- 
125 mg 
MDMA 
91.6 (19.7) 54.6 (31.9) -37.0 (20.9) 0.01 
a as compared to 40 mg group 
 
Table 3 CAPS-IV PTSD diagnostic criteria met post 2 blinded sessions, # (%) 
 Baseline Post 2 blinded Sessions 
40 mg MDMA (n = 6) Yes 6 (100%) 
No 0 (0%) 
Yes 4 (66.7%) 
No 2 (33.3%) 
125 mg MDMA (n = 12) Yes 13a (100%) 
No 0 (0%) 
Yes 7 (58.3%) 
No 5 (41.7%) 
a n=13 at baseline but one patient withdrew 
Table 4 Analysis of Treatment Efficacy 
CER EER ABI RBI NNT 
0.667 0.583 0.084 0.13 12 
 
Mithoefer et al.7 published a double blind randomized control study in 2018 that assessed 
the efficacy and safety of MAP specifically in veterans and first responders who were being 
treated at an outpatient psychiatric clinic in the United States. The study design was the same as 
that used in the Ot’lora et al. study, with the addition of two more 90-minute integrative sessions 
after the one week of follow up phone calls.  
Four SAEs were reported. Three of these were determined to be unrelated to the study 
drug. One participant had premature ventricular contractions at baseline, which increased in the 
crossover portion of the study and required an overnight hospital stay for observation.7 The 
patient fully recovered without evidence of lasting damage, but the SAE was considered possibly 
related to the study drug.7 
In total, 26 participants met criteria and were randomized to one of three different 
MDMA dose groups. There were seven participants in the 30 mg group, seven participants in the 
75 mg group, and 12 participants in the 125 mg group. This review focuses on the primary 
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endpoint findings for the 30 mg and 125 mg groups. All of the participants who were 
randomized completed the primary outcome assessments and were included in the analysis. The 
primary outcome for this study was the mean change in CAPS-IV total scores between baseline 
and one month after the completion of the second blinded session. These scores were analyzed 
using an ANOVA with α = 0.05. Descriptive statistics were used to convey the percentage of 
subjects that no longer met CAPS-IV PTSD diagnostic criteria at the primary endpoint. Pre- and 
post-treatment values are summarized in Tables 5 and 6. 
The 30 mg group had a mean CAPS-IV score of 87.4 at baseline and a post-experimental 
session score of 76.0, which represents an 11.4 decrease.7 The 125 mg group had a mean CAPS-
IV score of 89.7 at baseline and a post-experimental session score of 45.3, which is a 44.3 
decrease from baseline with a p = 0.004 compared to the 30 mg group.7 
At baseline, all participants in the 30 mg and 125 mg groups met CAPS-IV criteria for 
the diagnosis of PTSD. After two blinded MDMA sessions, 2 of the 7 subjects (29%) in the 30 
mg group and 7 of the 12 subjects (58%) in the 125 mg group no longer met CAPS-IV criteria 
for PTSD.7 
The CER was 0.710, the EER was 0.420, the ABI was 0.290, the RBI was 0.400, and the 
NNT was 4. These values are summarized in Table 7. 
Table 5 CAPS-IV total scores, mean (SD) 
 Baseline Post 2 blinded 
sessions 
Change P Valuea 
30 mg MDMA 87.4 (14.1) 76.0 (23.4) -11.4 (12.7) -- 
125 mg 
MDMA 
89.7 (17.3) 45.3 (33.8) -44.3 (28.7) 0.004 
a as compared to 40 mg group 
Table 6 CAPS-IV PTSD diagnostic criteria met post 2 blinded sessions, yes or no (%) 
 Baseline Post 2 blinded Sessions 
30 mg MDMA (n = 7) Yes 7 (100%) 
No 0 (0%) 
Yes 5 (71%) 
No 2 (29%) 
125 mg MDMA (n = 12) Yes 12 (100%) 
No 0 (0%) 
Yes 5 (42%) 
No 7 (58%) 
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Table 7 Analysis of Treatment Efficacy 
CER EER ABI RBI NNT 
0.710 0.420 0.290 0.400 4 
  
Wagner et al.8 published a randomized, double blind, placebo controlled trial in 2017 that 
investigated the role of MAP and symptom improvement by evaluating changes in openness and 
neuroticism personality traits as measured by the NEO PI-R. The study design was very similar 
to the studies already discussed, with a few key differences: participants were randomized to a 
placebo group or 125mg MDMA group, only two introductory psychotherapy sessions were 
completed prior to beginning experimental sessions, and study measures were collected at 
baseline then four days after each experimental session rather than one month later. As with the 
other studies being reviewed, only the blinded portion of this study will be discussed. There were 
no drug related SAEs reported in this study.8 
 In total, 23 participants were enrolled but only 20 completed the experimental sessions, 
baseline testing, and follow-up testing at the primary endpoint. Two participants withdrew before 
the second experimental session.8 One resumed a medication that made him ineligible to 
participate, and the other felt the travel demands were too difficult.8 A third subject was removed 
after it was discovered that he did not meet the criteria for treatment resistant PTSD.8  
 Twelve subjects were randomized to the MDMA group and had baseline NEO PI-R 
scores of 67.67 and 54.58 for neuroticism and openness respectively.8 After the experimental 
sessions, the neuroticism score was 55.833 and the openness score was 57.75.8 The placebo 
group had a baseline score of 65.88 and 63.12 for neuroticism and openness respectively.8 The 
neuroticism score dropped to 60.62 and the openness score to 60.00 after follow up testing.8 
There were no significant differences between groups for openness or neuroticism at baseline 
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compared to follow up because p was > 0.05 for all measures. These findings are summarized in 
Table 8.  
 The mean change between baseline and follow up neuroticism values for the MDMA 
group was 11.837, indicating that participants had lower neuroticism scores at follow up 
compared to baseline. The mean change between openness values for the MDMA group was 
negative 3.17, indicating that participants had higher openness scores at follow up compared to 
baseline. The mean change between neuroticism values at baseline to follow up for the placebo 
group was 5.26, indicating that baseline scores were higher than follow up scores. The mean 
change between openness values for the placebo group was 3.12, indicating that follow up scores 
were lower than at baseline. In other words, participants receiving placebo were less neurotic, 
though to a smaller degree than in the MDMA group, and less open at follow up compared to 
baseline. These findings are summarized in Table 9. 
Table 8 NEO scores at baseline and 2-month follow-up 
Variable MDMA group Placebo group P value 
Neuroticism baseline 67.67 (14.52) 65.88 (11.43) 0.773 
Neuroticism follow up 55.833 (15.16) 60.62 (6.65) 0.414 
Openness baseline 54.58 (15.88) 63.12 (6.66) 0.170 
Openness follow up 57.75 (12.52) 60.00 (8.30) 0.662 
Table 9 Analysis of Treatment Efficacy 
Variable Mean Change MDMA Mean Change Placebo 
Neuroticism +11.837 +5.26 
Openness -3.17 +3.12 
 
DISCUSSION 
 In the RCT conducted by Mithoefer et al., there was a larger CAPS-IV mean difference 
for the 125 mg group compared to the 30 mg group, with a statistically significant p-value of 
0.004.7 This indicates symptom improvement was greater for the experimental group than for the 
control group. Both Mithoefer et al. and Ot’lora et al. found that more participants in the 125 mg 
groups no longer met CAPS-IV diagnostic criteria after intervention compared to the lower 
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inactive dose groups, which supports that MAP results in greater symptom improvement for the 
experimental groups than for the control groups.6,7  
Although Ot’lora et al. found a greater decrease in CAPS-IV scores for the 125 mg 
MDMA group than the 40 mg MDMA group, this difference was not statistically significant in 
the ITT analysis (p=0.27). It was significant in the PP analysis (p=0.01) once data from four 
participants was removed.6 The authors attributed this disparity between sets to the CAPS-IV 
score of the individual from the 40 mg group who prematurely withdrew from the study after 
feeling that she had made satisfactory progress after one experimental treatment. When this 
outlier was removed, the group differences reached significance. However, it is important to 
recognize that the sample size for the study was initially small, and eliminating data from four 
additional participants in the PP analysis further reduces the validity of this finding. Wagner et 
al. found that participants in the MDMA group had higher increases in openness and larger 
decreases in neuroticism compared to the placebo control group, which would indicate that MAP 
is correlated to positive changes in these personality traits, but these findings weren’t statistically 
significant and may have been due to chance.8 
These studies were limited by their small, homogenous samples, making it difficult to 
generalize these findings across race and gender. Achieving effective blinding is also difficult to 
maintain when using a psychoactive drug. Many subjects and study staff were able to correctly 
guess group assignments, which may have introduced bias into the results.  
Even if more than one of these studies had been able to demonstrate that MAP improved 
PTSD symptoms, the feasibility of using this drug as an adjunctive treatment remains 
questionable. Accessibility and abuse potential must be considered, as it is still a Schedule I drug 
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in the United States. Even if the drug were readily available, patients must be in relatively good 
health and have extensive, potentially burdensome monitoring to ensure their safety.  
CONCLUSION  
 Based on the results presented, there is not enough statistically significant data to 
conclude that MAP improves PTSD symptoms. The small sample sizes, homogeneity of the 
sample sizes, and outlier data challenge the generalizability and significance of the findings in 
these studies. Future studies with larger, heterogenous populations should be conducted in order 
to more definitively conclude whether or not MDMA improves PTSD symptoms. It’d also be 
important determine how many sessions need to be completed before efficacy is attained, and 
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